The Food and Drug Administration has approved Zoryve (roflumilast) topical foam, 0.3% for plaque psoriasis of the scalp and body.

Plaque psoriasis is the most common type of psoriasis and the one that often appears on the scalp. It causes raised ... making them easier to remove. Coal tar products are available OTC as ...

The U.S. Food and Drug Administration has approved Zoryve (roflumilast) topical foam 0.3 percent for the treatment of plaque ...

The programme comprises two Phase III trials, ONWARD1 and ONWARD2, and an optional long-term extension trial, ONWARD3.

Stull said that a number of prescription treatments exist for topical psoriasis, such as steroids and injectable therapies, ...

The 0.3% foam formulation of roflumilast was previously approved for the treatment of seborrheic dermatitis in adults and ...

Topical roflumilast 0.3% cream has been approved by the FDA to treat plaque psoriasis in patients 12 years and older since ...

Plaque psoriasis is characterized by raised ... Scalp psoriasis shows up as itchy, scaly patches on the scalp that may bleed if you try to remove them. About half of people who have psoriasis ...

These plaques are typically itchy and painful. Scalp psoriasis is typically caused by plaque psoriasis, an autoimmune disorder. The immune system overreacts, causing inflammation. This ...

A total of 432 patients (56.3% women) aged 12 and older with psoriasis on the scalp and body were randomly assigned to two groups, one of which used roflumilast foam 0.3% once a day for eight ...

Once-daily roflumilast foam, 0.3% (Zoryve) significantly improved scalp and body symptoms of plaque psoriasis in a phase III trial. Improvements in scalp itch were also greater for patients ...